Apimeds Pharmaceuticals US (APUS) Current Assets (2023 - 2025)

Apimeds Pharmaceuticals US's Current Assets history runs 3 years deep, the most recent figure standing at $14.0 million for Q4 2025.

• Quarterly Current Assets rose 106998.56% year-over-year to $14.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.0 million (up 106998.56% YoY) and the FY2025 annual result came in at $14.0 million, up 106998.56% from the prior year.
• Current Assets was $14.0 million for Q4 2025 at Apimeds Pharmaceuticals US, up from $9.1 million in the prior quarter.
• Across five years, Current Assets topped out at $14.0 million in Q4 2025 and bottomed at $13057.0 in Q4 2024.
• A 3-year average of $5.7 million and a median of $4.8 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets plunged 96.91% — and 2025, when it soared 106998.56%.
• Apimeds Pharmaceuticals US's Current Assets stood at $422076.0 in 2023, then plunged by 96.91% to $13057.0 in 2024, then surged by 106998.56% to $14.0 million in 2025.
• Business Quant data shows APUS's Current Assets at $14.0 million in Q4 2025, $9.1 million in Q3 2025, and $10.3 million in Q2 2025.